Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-294-88 D-1511-2014
Class II · Moderate risk

Cephalexin Capsules

CGMP Deviations: These products are being recalled because they were manufactured with active pharmaceutical ingredients (APIs) that were not manufactured with good manufacturing practices.

Terminated cGMP deviation Caraco Pharmaceutical Laboratories, Ltd. NDC 62756-293-88 D-1510-2014
Class III · Low risk

Lortuss Ex

Does Not Meet Monograph: Phenylephrine and pseudoephedrine are below monograph specifications, and label inaccurately contains wording "Rx Only".

Terminated Unapproved drug Poly Pharmaceuticals, Inc D-1432-2014
Class III · Low risk

Poly-Tussin Ac Liquid

Does Not Meet Monograph: Phenylephrine and pseudoephedrine are below monograph specifications, and label inaccurately contains wording "Rx Only".

Terminated Unapproved drug Poly Pharmaceuticals, Inc D-1431-2014
Class II · Moderate risk

Glutathione Injection USP

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1533-2014
Class II · Moderate risk

L-Carnitine Injection USP 100 mg/ml

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1532-2014
Class II · Moderate risk

G.A.C. 375 Injection USP

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1531-2014
Class II · Moderate risk

Lipo 8 Injection USP 200 mg/ml

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1530-2014
Class II · Moderate risk

MIC Injection USP

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1525-2014
Class II · Moderate risk

Vitamin B6 Pyridoxine HCL for Injection USP

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1523-2014
Class II · Moderate risk

Vitamin B12 Cyanocobalamin Injection USP 1000 mcg/ml

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1522-2014
Class II · Moderate risk

BCAA 4% Branched Chain Amino Acid Injection USP

Marketed without an Approved NDA/ANDA; IM and SQ injectable products are being recalled because the manufacturing firm is not registered with the FDA as a drug manufacturer

Terminated Unapproved drug Medical Supply Liquidators Llc D-1521-2014
Class III · Low risk

Diltiazem HCl Extended Release Capsules

Failed Impurities/Degradation Specifications: High out-of-specification results for a related compound obtained during routine stability testing.

Terminated Impurity / degradation Mylan Pharmaceuticals Inc. NDC 0378-5220-05 D-1557-2014

Recalls by year